Billy Evans, partner of Theranos founder Elizabeth Holmes, is launching a new blood-testing venture called Haemanthus, raising eyebrows and questions about repeating past mistakes in health technology.
Billy Evans, partner of Theranos founder Elizabeth Holmes, unveils Haemanthus, a startup aiming to revolutionize health optimization through advanced blood testing. With ambitions to raise over $50 million, this venture echoes Theranos' controversial legacy. Is it a groundbreaking innovation or a repeat of past mistakes?
A recent survey reveals that older Americans are increasingly proactive about Alzheimer's, with 79% wanting to know if they have the disease before symptoms arise. Many would opt for a blood test and are open to new drug treatments.
A groundbreaking urine test for prostate cancer has shown remarkable accuracy, outperforming traditional blood tests. Set to enter clinical trials, this innovation may make routine screenings a reality, potentially saving thousands of lives.
A startling rise in colon cancer diagnoses among those under 55 has researchers investigating a crucial factor: vitamin D levels. Discover how a simple blood test could reveal your risk and what steps you can take to protect your health.
A new blood test developed by neuroscientists can reveal whether Alzheimer's is affecting a patient's memory, providing crucial insights for early diagnosis and treatment. This innovation could transform how we understand and address Alzheimer's disease.
A new blood test developed by experts at Washington University and Lund University could change the way Alzheimer’s is diagnosed and treated, identifying disease progression and guiding personalized care.
A groundbreaking blood test developed by researchers may change how Alzheimer's is diagnosed and treated, providing insights into the disease's progression and helping identify suitable medications.
US court upholds convictions of Theranos' founder Elizabeth Holmes and President Ramesh “Sunny” Balwani for defrauding investors in the failed blood testing startup once valued at $9 billion.
